Sino Biopharm (01177.HK) announced that from May 7, 2024 to September 30, 2024, Hengrui will cumulatively purchase approximately 0.187 billion shares under the stock incentive plan, with a total cost of approximately 0.551 billion Hong Kong dollars, and a remaining share purchase quota of approximately 0.5 billion RMB. Hengrui will continue to purchase shares according to the current stock incentive plan depending on market conditions.
中国生物制药：正大天晴据股份激励计划购买了约5.51亿港元股份
sino biopharm: China Grand Pharmaceutical has purchased approximately 0.551 billion Hong Kong dollars in shares under the stock incentive plan.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.